济宁治疗癫痫医院哪儿有山东癫痫老年癫痫怎么样,江苏治羊羔疯病那家医院好,青岛治疗羊羔疯的有效方法,河北较好的医院羊羔疯专病,潍坊冶癫痫哪里医院会治好,威海医院羊癫疯专病那个好,枣庄治癫痫病哪里好

The two Los Angeles County Sheriff's Deputies who were shot in an ambush-style attack on Saturday are out of surgery and expected to survive their injuries, according to reports from ABC News, CNN and The Washington Post.Alex Villanueva, the LA County Sheriff, told CNN Sunday night that it looked like the two injured officers would be able to recover from their injuries, but the long-term impacts on their health are currenlty unknown."We'll see what the long-term impact is. We don't know that yet, but they survived the worst," Villanueva reportedly said during a community dialogue event, according to CNN.A suspect ambushed the two officers as they sat in a police car near a Compton metro station on Saturday night. Surveillance video posted by the department on Twitter shows a man walk up to the passenger side of the patrol car, raise a gun to the window and open fire. The deputies were able to radio for help as the suspect ran away.The two injured deputies, a 31-year-old woman and a mother and a 24-year-old man, were relative newcomers in the department, having been on the job for 14 months.According to ABC News, officials are offering a 0,000 reward for information that could lead to the suspect's arrest.Politicians widely condemned the shooting. On Sunday morning, President Donald Trump called for a "fast trial death penalty for the killer" if the deputies were to succumb to their injuries."Only way to stop this!" Trump added. 1463

The US House of Representatives will vote on whether to legalize marijuana across the country in September. This would be the first time a chamber of Congress has ever voted on removing marijuana from the Controlled Substances Act.Cannabis was included as what is called a Schedule I drug under the Controlled Substances Act in 1970. Schedule I drugs are defined as having a high potential for abuse and no medical benefit. Other Schedule I drugs include heroin, LSD, ecstasy and peyote.On Friday, representatives were informed the MORE Act will come up for a vote in the September work period of the House.The MORE Act - Marijuana Opportunity Reinvestment and Expungement Act - will expunge some cannabis records and create grant opportunities for people who have been negatively impacted by the criminalization of marijuana in addition to removing it from its Schedule I classification, according to Politico.Marijuana is already legal in 11 states, despite the federal designation as a Schedule I drug.Senate Majority Leader Mitch McConnell is opposed to the act, and some say the odds of it passing the senate are very slim.Even if the MORE Act passes both chambers of Congress, it would not make sales of marijuana legal. Regulation of marijuana would be left to states to decide how to handle it. 1310

The world’s population has been growing, spiking in the last few centuries, and now sits around 7.6 billion. A study published this week suggests global population will peak around the year 2064 at roughly 9.73 billion people.Researchers looking at the models believe the world’s population will then begin declining, reaching roughly 8.79 billion in the year 2100. Their reasoning for the decline is that “continued trends in female educational attainment and access to contraception will hasten declines in fertility and slow population growth.”According to the study, funded in part by the Bill and Melinda Gates Foundation and published in The Lancet, the five largest countries, population-wise, in 2100 are projected to be India, Nigeria, China, the U.S. and Pakistan. They are projecting America will have a population of roughly 336 million people in 2100. Currently, there are an estimated 331 million people living in the U.S.The average life expectancy in 2100 will be around 80 years old. The current global life expectancy is estimated at 72 years old. 1073

The US called on Turkey to not follow through on threats to attack US-backed forces in Syria Wednesday, an incursion the Pentagon warned could threaten US personnel and derail the fight against ISIS."Unilateral military action into northeast Syria by any party, particularly as US personnel may be present or in the vicinity, is of grave concern. We would find any such actions unacceptable," Commander Sean Robertson, a spokesman for the Department of Defense, told CNN."We believe this dialogue is the only way to secure the border area in a sustainable manner, and believe that uncoordinated military operations will undermine that shared interest," he added.Earlier on Wednesday, Turkey's President Recep Tayyip Erdogan said in a televised speech that Turkish troops would launch a military operation east of the Euphrates in Syria, an operation aimed at targeting Kurdish militants.The US troops in Syria regularly work with Kurdish elements of the Syrian Democratic Forces as part of their campaign against ISIS.Turkey sees all Kurdish forces in in Northern Syria as an extension of the Kurdistan Workers' Party (PKK), listed as terror group by the US and the EU. The US does not share Turkey's view."Our target is definitely not American troops. It is the members of terror organization operating in the region. I want to emphasize this," Erdogan added, saying that he expected the operation to begin "in a couple of days."Secretary of Defense James Mattis recently directed US troops to establish a series of observation posts in the northeast Syria border region as part of an effort to reduce tensions between Turkey and the US-backed Syrian Democratic Forces.Two US officials told CNN that while the US has observed additional Turkish forces arriving in the area, at this point in time it is assessed that Turkey does not have enough troops in the area to conduct the type of operation in the timeline outlined by Erdogan.However the threat of cross-border shelling remains, potentially putting US troops there at risk.Previous cross-border clashes caused the Syrian Democratic Forces to suspend their hard-fought offensive against the ISIS-held town of Hajin, the terror group's last remaining redoubt east of the Euphrates River."The campaign against ISIS is not over. Coalition forces are working closely with the Syrian Democratic Forces who are in the midst of offensive operations against ISIS in the Middle Euphrates River Valley," Robertson, the Pentagon spokesman said."We should not and cannot allow ISIS to breathe at this critical point or we will jeopardize the significant gains we have made alongside our Coalition partners and risk allowing ISIS to resurge," he added. 2703

The Wake Forest Institute for Regenerative Medicine says it has a new use for its bioprinting system. In the past they've 3D printed normal-size organs and tissues in hopes of someday implanting them in patients.For the coronavirus, the lab is creating organs using human cells that can be as small as a pinhead. They're focusing on the organs most likely to be infected by the disease. like the lungs.“And so we've been playing with a number of agents to, on both prongs what can make it more infective, what can make it less infective to try to sort this out for the future,” Anthony Atala, director for the institute said.Atala says he hopes the system will help in testing drugs before they hit the market.Drug companies do extensive testing and clinical trials in people before releasing a new medication.Atala says sometimes those companies find no serious side effects, but then years later, discover that it's toxic to patients taking it. Atala says testing a drug using the bioprinting system can tell if a drug is toxic in weeks instead of after years on the market.“Even though we've used the tool extensively for toxicity testing, it's also a tool that can be used for screening,” Atala said. “So we can test agents that are currently being considered for testing against COVID and test the efficacy of the treatment on miniature human organs made up of normal cells”To be clear, Atala said drug tests on 3D printer organs are not meant to replace clinical trials in humans, be are an added step to better predict what will happen in those trials. 1567